Kynam Capital Management Reduces Syndax Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 21 2026
0mins
Should l Buy SNDX?
Source: Fool
- Share Reduction Details: Kynam Capital Management disclosed in a February 17, 2026 SEC filing that it sold 469,041 shares of Syndax Pharmaceuticals, valued at approximately $8.18 million, indicating a cautious stance towards the company's future prospects.
- Position Percentage Change: Following the sale, Syndax now accounts for 10.81% of Kynam's reportable assets, reflecting a significant yet measured adjustment in their holdings, which still signals confidence in the company's long-term potential.
- Company Financial Performance: Syndax Pharmaceuticals has seen its stock price surge 72% over the past year, achieving a market capitalization of $2.1 billion and total revenue of $172.4 million, despite a net loss of $285.4 million, highlighting the tension between growth and profitability.
- Market Reaction Analysis: The successful launch of new therapies has driven revenue growth for Syndax, particularly with Revuforj contributing approximately $124.8 million, although the company continues to face high R&D and commercialization costs, necessitating investor attention on its path to profitability.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNDX
Wall Street analysts forecast SNDX stock price to rise
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 22.480
Low
27.00
Averages
39.11
High
56.00
Current: 22.480
Low
27.00
Averages
39.11
High
56.00
About SNDX
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DAFNA Capital Reduces Stake in Syndax Pharmaceuticals
- Share Reduction Details: DAFNA Capital reported in its February 17, 2026 SEC filing that it sold 222,847 shares of Syndax Pharmaceuticals in Q4, with an estimated transaction value of $3.89 million, reflecting a cautious outlook on the company's future performance.
- Ownership Percentage Change: Following the sale, DAFNA's stake in Syndax decreased to 1.36% from 1.90% in the previous quarter, indicating a strategic adjustment in its investment portfolio.
- Market Performance Comparison: As of last Friday, Syndax's stock price stood at $24.23, marking a 72% increase over the past year, significantly outperforming the S&P 500's 15% rise during the same period, highlighting its strong position in the biopharmaceutical sector.
- Company Growth Prospects: Syndax focuses on developing oncology therapies, and despite facing high operating costs and ongoing losses, its $172 million in 2025 sales and rapidly scaling commercial products demonstrate its potential in transitioning from clinical to commercial-stage biotech.
See More
DAFNA Capital Management Reduces SNDX Holdings
- Share Reduction Details: DAFNA Capital Management sold 222,847 shares of Syndax Pharmaceuticals (SNDX) in Q4, with an estimated transaction value of approximately $3.89 million, indicating a cautious stance towards the stock.
- Position Value Decline: The value of DAFNA's SNDX holdings decreased by $1.87 million by quarter-end, reflecting both trading activities and price movements, with the current position representing 1.4% of reportable AUM.
- Company Overview: Syndax Pharmaceuticals focuses on developing novel cancer therapies, generating approximately $172 million in sales for 2025, showcasing a successful transition from clinical to commercial stages, albeit with higher operating costs and ongoing losses.
- Investor Caution: Despite Syndax's innovative potential in the biopharmaceutical sector, it was not included in the current top investment stock list by analysts, advising investors to carefully consider market volatility before making decisions.
See More
Kynam Capital Management Reduces Syndax Holdings
- Share Reduction Details: Kynam Capital Management disclosed in a February 17, 2026 SEC filing that it sold 469,041 shares of Syndax Pharmaceuticals, valued at approximately $8.18 million, indicating a cautious stance towards the company's future prospects.
- Position Percentage Change: Following the sale, Syndax now accounts for 10.81% of Kynam's reportable assets, reflecting a significant yet measured adjustment in their holdings, which still signals confidence in the company's long-term potential.
- Company Financial Performance: Syndax Pharmaceuticals has seen its stock price surge 72% over the past year, achieving a market capitalization of $2.1 billion and total revenue of $172.4 million, despite a net loss of $285.4 million, highlighting the tension between growth and profitability.
- Market Reaction Analysis: The successful launch of new therapies has driven revenue growth for Syndax, particularly with Revuforj contributing approximately $124.8 million, although the company continues to face high R&D and commercialization costs, necessitating investor attention on its path to profitability.
See More
Kynam Capital Reduces Syndax Stake
- Share Reduction Transaction: Kynam Capital reduced its stake in Syndax Pharmaceuticals by 469,041 shares in Q4 2025, with an estimated trade value of $8.18 million, reflecting the fund's flexible adjustment strategy amid market fluctuations.
- Holding Value Increase: Despite the reduction, Kynam Capital's position in Syndax saw a quarter-end value increase of $38.07 million, indicating strong stock performance and positive impacts from trading activities.
- Company Financial Performance: Syndax Pharmaceuticals generated approximately $172 million in total revenue last year, with Revuforj contributing about $124.8 million, showcasing growing market acceptance of its new therapies, although the company still faced a net loss of around $285 million.
- Portfolio Adjustment: Kynam Capital's Syndax holdings still account for over 10% of its assets, indicating that despite the reduction, the fund maintains confidence in the company's long-term prospects, reflecting a strategic positioning within the biotech sector.
See More
Kynam Capital Management Cuts Viridian Stake by Over $81 Million
- Stake Reduction: Kynam Capital Management sold 2,957,386 shares of Viridian Therapeutics in Q4 2026, with an estimated transaction value of $81.11 million, indicating a cautious outlook on the company's future performance.
- Holding Proportion Change: Following this transaction, Kynam's stake in Viridian decreased to 2.92%, reflecting a reassessment of asset allocation in its 13F report, which may impact investor confidence in the company.
- Market Performance: Viridian's stock price has surged 76% over the past year, currently priced at $26.98, significantly outperforming the S&P 500's roughly 15% gain, indicating strong market demand for its biotech products.
- R&D Expenditure: Despite facing nearly $339 million in R&D costs and an annual net loss of about $343 million, Viridian's cash reserves of approximately $875 million at year-end provide a financial cushion for future clinical trials and product launches.
See More
Kynam Capital Reduces Stake in Cogent Biosciences by $48 Million
- Share Reduction Details: Kynam Capital disclosed in an SEC filing on February 17, 2026, that it sold 1,720,949 shares of Cogent Biosciences in Q4, with an estimated transaction value of $48.38 million, indicating a cautious approach towards the company's future prospects.
- Ownership Proportion Change: Following this sale, Cogent Biosciences now represents 13.99% of Kynam's reported AUM, yet it remains the fund's largest holding, reflecting ongoing confidence in its core investment despite the reduction.
- Market Performance Analysis: Cogent's stock price surged 360% over the past year, significantly outperforming the S&P 500's 15% gain during the same period, highlighting its strong performance and market recognition in the biotech sector.
- Future Outlook: Cogent's lead product, bezuclastinib, received FDA acceptance, with a target decision date set for December 30, 2026, and with $900.8 million in cash reserves, the company is well-positioned to support future R&D and market expansion efforts.
See More
DAFNA Capital Reduces Stake in Syndax Pharmaceuticals
- Share Reduction Details: DAFNA Capital reported in its February 17, 2026 SEC filing that it sold 222,847 shares of Syndax Pharmaceuticals in Q4, with an estimated transaction value of $3.89 million, reflecting a cautious outlook on the company's future performance.
- Ownership Percentage Change: Following the sale, DAFNA's stake in Syndax decreased to 1.36% from 1.90% in the previous quarter, indicating a strategic adjustment in its investment portfolio.
- Market Performance Comparison: As of last Friday, Syndax's stock price stood at $24.23, marking a 72% increase over the past year, significantly outperforming the S&P 500's 15% rise during the same period, highlighting its strong position in the biopharmaceutical sector.
- Company Growth Prospects: Syndax focuses on developing oncology therapies, and despite facing high operating costs and ongoing losses, its $172 million in 2025 sales and rapidly scaling commercial products demonstrate its potential in transitioning from clinical to commercial-stage biotech.
See More
DAFNA Capital Management Reduces SNDX Holdings
- Share Reduction Details: DAFNA Capital Management sold 222,847 shares of Syndax Pharmaceuticals (SNDX) in Q4, with an estimated transaction value of approximately $3.89 million, indicating a cautious stance towards the stock.
- Position Value Decline: The value of DAFNA's SNDX holdings decreased by $1.87 million by quarter-end, reflecting both trading activities and price movements, with the current position representing 1.4% of reportable AUM.
- Company Overview: Syndax Pharmaceuticals focuses on developing novel cancer therapies, generating approximately $172 million in sales for 2025, showcasing a successful transition from clinical to commercial stages, albeit with higher operating costs and ongoing losses.
- Investor Caution: Despite Syndax's innovative potential in the biopharmaceutical sector, it was not included in the current top investment stock list by analysts, advising investors to carefully consider market volatility before making decisions.
See More
Kynam Capital Management Reduces Syndax Holdings
- Share Reduction Details: Kynam Capital Management disclosed in a February 17, 2026 SEC filing that it sold 469,041 shares of Syndax Pharmaceuticals, valued at approximately $8.18 million, indicating a cautious stance towards the company's future prospects.
- Position Percentage Change: Following the sale, Syndax now accounts for 10.81% of Kynam's reportable assets, reflecting a significant yet measured adjustment in their holdings, which still signals confidence in the company's long-term potential.
- Company Financial Performance: Syndax Pharmaceuticals has seen its stock price surge 72% over the past year, achieving a market capitalization of $2.1 billion and total revenue of $172.4 million, despite a net loss of $285.4 million, highlighting the tension between growth and profitability.
- Market Reaction Analysis: The successful launch of new therapies has driven revenue growth for Syndax, particularly with Revuforj contributing approximately $124.8 million, although the company continues to face high R&D and commercialization costs, necessitating investor attention on its path to profitability.
See More
Kynam Capital Reduces Syndax Stake
- Share Reduction Transaction: Kynam Capital reduced its stake in Syndax Pharmaceuticals by 469,041 shares in Q4 2025, with an estimated trade value of $8.18 million, reflecting the fund's flexible adjustment strategy amid market fluctuations.
- Holding Value Increase: Despite the reduction, Kynam Capital's position in Syndax saw a quarter-end value increase of $38.07 million, indicating strong stock performance and positive impacts from trading activities.
- Company Financial Performance: Syndax Pharmaceuticals generated approximately $172 million in total revenue last year, with Revuforj contributing about $124.8 million, showcasing growing market acceptance of its new therapies, although the company still faced a net loss of around $285 million.
- Portfolio Adjustment: Kynam Capital's Syndax holdings still account for over 10% of its assets, indicating that despite the reduction, the fund maintains confidence in the company's long-term prospects, reflecting a strategic positioning within the biotech sector.
See More
Kynam Capital Management Cuts Viridian Stake by Over $81 Million
- Stake Reduction: Kynam Capital Management sold 2,957,386 shares of Viridian Therapeutics in Q4 2026, with an estimated transaction value of $81.11 million, indicating a cautious outlook on the company's future performance.
- Holding Proportion Change: Following this transaction, Kynam's stake in Viridian decreased to 2.92%, reflecting a reassessment of asset allocation in its 13F report, which may impact investor confidence in the company.
- Market Performance: Viridian's stock price has surged 76% over the past year, currently priced at $26.98, significantly outperforming the S&P 500's roughly 15% gain, indicating strong market demand for its biotech products.
- R&D Expenditure: Despite facing nearly $339 million in R&D costs and an annual net loss of about $343 million, Viridian's cash reserves of approximately $875 million at year-end provide a financial cushion for future clinical trials and product launches.
See More
Kynam Capital Reduces Stake in Cogent Biosciences by $48 Million
- Share Reduction Details: Kynam Capital disclosed in an SEC filing on February 17, 2026, that it sold 1,720,949 shares of Cogent Biosciences in Q4, with an estimated transaction value of $48.38 million, indicating a cautious approach towards the company's future prospects.
- Ownership Proportion Change: Following this sale, Cogent Biosciences now represents 13.99% of Kynam's reported AUM, yet it remains the fund's largest holding, reflecting ongoing confidence in its core investment despite the reduction.
- Market Performance Analysis: Cogent's stock price surged 360% over the past year, significantly outperforming the S&P 500's 15% gain during the same period, highlighting its strong performance and market recognition in the biotech sector.
- Future Outlook: Cogent's lead product, bezuclastinib, received FDA acceptance, with a target decision date set for December 30, 2026, and with $900.8 million in cash reserves, the company is well-positioned to support future R&D and market expansion efforts.
See More
